RxDoctor Payments Data

Paul White, MD

Gynecology · Fresno, CANPI 1326254624

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (50.8%), food and beverage and education — rather than concentrated in one kind of arrangement. Coloplast accounts for 66.3% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2023 at $1,815 and has fallen 98.4% since, to $30 in 2025.

$4,378in general payments, 2019–2025

Across 70 payments — averaging $62.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$3K
  • Medtronic$771
  • AbbVie$350
  • W. L. Gore & Associates, Inc.$138
  • Pfizer$54
  • Galderma Laboratories, L.p.$43
  • plus $119 from 6 others

What the payments were for

  • Travel & lodging$2,22451%
  • Food & beverage$2,08748%
  • Education$682%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,378 in reported general payments places this provider in the 80th percentile of 247 gynecology providers in California.

See all gynecology providers in California

Medicare billing

Part B allowed, 2024
$44,296
Medicare patients
55
Services billed
230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron76$52,009
PremarinEstrogens, Conjugated41$17,285
Estradiol133$10,630
Mirabegron ErMirabegron16$8,308
Darifenacin ErDarifenacin Hydrobromide28$4,004
Trospium Chloride ErTrospium Chloride26$3,393
Gabapentin112$1,490
Fesoterodine Fumarate ErFesoterodine Fumarate11$1,082
Solifenacin Succinate17$459
Ibuprofen37$318
Oxybutynin Chloride ErOxybutynin Chloride11$246
NitrofurantoinNitrofurantoin Macrocrystal17$158
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst12$87
Fluconazole11$52
Tramadol Hcl20$28

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$54$17,28541 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 247 gynecology providers in California.

Other gynecology in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →